Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs

To cite this version:
Hong S. Lee, Stephan Ripke, Benjamin M. Neale, Stephen V. Faraone, Shaun M. Purcell, et al.. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics, 2013, 45 (9), pp.984-994. 10.1038/ng.2711. inserm-00864642

HAL Id: inserm-00864642
https://inserm.hal.science/inserm-00864642
Submitted on 28 Mar 2014

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs

Cross-Disorder Group of the Psychiatric Genomics Consortium

Correspondence to

Naomi R. Wray

The University of Queensland, Queensland Brain Institute, Brisbane, QLD, 4067 Australia.

naomi.wray@uq.edu.au

Summary paragraph

Most psychiatric disorders are moderately to highly heritable. The degree to which genetic variation is unique to individual disorders versus shared across disorders is unclear. We use genome-wide genotype data from the Psychiatric Genomics Consortium (PGC) of cases and controls for schizophrenia (SCZ), bipolar disorder (BPD), major depressive disorder (MDD), autism spectrum disorders (ASD), and attention deficit hyperactivity disorder (ADHD). We apply univariate and bivariate methods for estimation of genetic variation within and covariation between disorders. SNPs explained 17-29% of the variance in liability. The genetic correlation calculated from common SNPs is high for SCZ/BPD (0.68±SE 0.04), moderate for SCZ/MDD (0.43±0.06), BPD/MDD (0.47±0.06), ADHD/MDD (0.32±0.07), low between SCZ/ASD (0.16±0.06), and non-significant for other pairs of disorders as well as with the negative control of Crohn's Disease. This empirical evidence for a shared genetic etiology between psychiatric disorders can inform nosology and encourages investigation of common pathophysologies for the related disorders.
Current classification of psychiatric disorders reflects clinical syndromes with largely unknown etiology and is based on historical descriptions provided by prominent clinicians over the last 125 years. Family (including twin and adoption) studies provide consistent evidence that genetic factors are involved in these syndromes. In principle, family studies allow quantification of shared genetic etiology, through estimation of heritability (the proportion of variance in liability attributable to additive genetic factors) of disorders and the genetic correlation between them. However, difficulties in ascertaining samples of sufficient size mean that estimates of genetic correlations are few. Nonetheless, family studies suggest correlated familial-genetic liabilities to BPD and SCZ, BPD and MDD and ASD and ADHD (Supplementary Table 1). Phenotypic and genetic overlap has also been suggested for ASD and SCZ, ASD and BPD, BPD and ADHD and MDD and ADHD. Some of these relationships have been supported by recent evidence of shared molecular risk factors, but the extent of these relationships remains unclear given the small proportion of risk associated with these individually identified variants.

The genomics era provides new opportunities to explore the shared genetic etiology of disorders. Genome-wide association studies (GWAS) assess common genetic polymorphisms (e.g., SNPs) at several hundred thousand positions in the genome. The experimental paradigm of GWAS is identification of individual variants associated with case-control status. However, these data can be used to estimate the total variance in liability explained by SNPs (“SNP-heritability”, $SNP-h^2$) through estimation of genetic similarities (relationships) between cases and controls using SNP genotypes. The pair-wise genetic relationships that contribute to the estimate are very small, but the large number of pairwise relationships in a case-control sample generates estimates with reasonable precision.
SNP-h^2 is an estimate of the total variance in liability to disease explained by the SNPs together. Genetic variation is estimated when case-case pairs and control-control pairs are, on average, more similar genome-wide than case-control pairs. The SNP-h^2 is a lower bound for the total narrow sense heritability, as the former cannot include contributions from causal variants not tagged by the measured SNPs, mostly less common and rare causal variants. A bivariate extension of these genome-wide methods estimates the genetic correlation (SNP-r_g) explained by SNPs between case-control samples collected independently for two disorders (see online Methods). The correlation is positive when the cases of one disorder show higher genetic similarity to the cases of the other disorder than to their controls. A negative correlation is possible if the cases of one disorder are less similar genome-wide to the cases of the other disorder than they are to controls. A genetic correlation of zero is estimated if the genome-wide relationship between cases of one disorder is the same with cases as with controls of the other disorder. As a correlation, a high SNP-r_g is achieved when the covariance term between the traits is similar in magnitude to the variance terms. Therefore, we also report the SNP-coheritability between pairs of disorders, which is the covariance between disorders on the liability scale and allows comparison of the shared liability attributable to SNPs on the same scale as the SNP-h^2.

Here, we apply the univariate and bivariate methods to the five disorders of the PGC: SCZ, BPD, MDD, ASD and ADHD analysed in the PGC cross-disorder group association study, together with additional ADHD data sets (Table 1).

RESULTS

SNP-heritabilities for the five disorders

In our linear mixed model we estimate the variance in case-control status explained by SNPs (heritability on the observed scale, CC in Table 1). Cases in case-control samples are highly ascertained compared to in the population, and since the different disorder cohorts
have different proportions of cases, the CC estimates are difficult to interpret and compare. For this reason, we report $SNP-h^2$ on the liability scale, in which a linear transformation is applied based on a user-specified estimate of the disorder risk of the study-base population (disorder risk, $K$). For each disorder we consider three values of $K$ (Table 1) and we convert the $SNP-h^2$ to a predicted risk to 1st-degree relatives ($SNP-\lambda_{1st}$) given $K$. We benchmark the $SNP-\lambda_{1st}$ risk to risk to 1st-degree relatives ($\lambda_{1st}$) consistent with estimates of heritabilities reported from family studies given $K$. Our estimates of $SNP-\lambda_{1st}$ are robust, and of $SNP-h^2$ are reasonably robust, to the likely range of $K$ and show that an important part of the heritabilities or familial risk estimated from family studies are associated with common SNPs. Twice the standard error of estimates approximates the magnitude of parameter that is possible to detect as significantly different from zero given the available sample sizes.

SNP-coheritabilities and SNP-correlations ($SNP-r_g$) between all pairwise combinations of disorders

The relationships between disorders are expressed as SNP-coheritabilities (Fig. 1). The $SNP-r_g$ is high for SCZ/BPD 0.68 (s.e. 0.04), moderate for SCZ/MDD 0.43 (0.06), BPD/MDD 0.47 (0.06), ADHD/MDD 0.32 (0.07), low between SCZ/ASD 0.16 (0.06), and non-significant for other pairs of disorders (Supplementary Table 1). The $SNP-r_g$ correlation is expected to be equal to the $r_g$ from family studies only if the genetic correlation is the same across the allelic frequency spectrum and if the linkage disequilibrium between genotyped and causal variants is similar for both disorders. The sample size for ASD is the smallest but still can detect correlations of $>|0.18|$ to be different from zero in bivariate analyses with all other disorders.

Our results provide empirical evidence that SCZ, BPD and MDD have a shared genetic etiology. Since some SCZ and BPD cohorts were collected in the same clinical environments,
we investigated possible impact of non-independent collection of SCZ/BPD samples sets but found no significant change in the estimates (Supplementary Table 2). The correlation between SCZ and ASD is significant but small (0.16 s.e. 0.06, p = 0.0071). In general, our analyses suggest that while common genetic variants contribute to both childhood-onset disorders (ASD, ADHD) and disorders usually diagnosed after childhood (SCZ, BPD, MDD), the sharing of common variants between them is modest.

The pattern of our results (i.e., which pairs of disorders demonstrate genetic overlap) is consistent with the polygenic profile score results from the PGC cross-disorder analyses. The profile score method uses SNP associations from one disorder to construct a linear predictor in another disorder. The profile scores explained small but significant proportions of the variance, expressed as Nagelkerke’s $R^2$ (maximum of 2.5% between SCZ and BPD).

To achieve a high $R^2$ requires accurate estimation of effect sizes of individual SNPs and depends on the size of the discovery sample. In contrast, our approach uses SNPs to estimate genome-wide similarities between pairs of individuals, resulting in unbiased estimates of the relationships between disorders, with larger sample sizes generating smaller standard errors of the estimates. Our estimates are on the liability scale, allowing direct comparison to genetic parameters estimated in family studies, whereas a genetic interpretation of Nagelkerke’s $R^2$ is less straightforward.

**Genomic partitioning of SNP-heritabilities and SNP-coheritabilities**

The heritabilities explained by SNPs can be partitioned according to SNP annotation by estimation of genetic similarity matrices from multiple, non-overlapping SNP sets. For the five disorders, and the five disorder pairs showing a significant SNP correlation, we partitioned the SNP-\(h^2\) and SNP-coheritabilities explained by functional annotation, allocating SNPs to one of three sets: i) in genes preferentially expressed in the central nervous system (CNS+)\(^{34,35}\), ii) in other genes and iii) not in genes, with genes defined with
50kb boundaries from their start/stop positions. The SNPs in the CNS+ gene set represented 0.20 of the total set, both in number and megabases. However, the proportion of the variance explained by SNPs attributable to this SNP set is significantly greater than 0.20 for SCZ (0.30, \( p = 7.6 \times 10^{-8} \)) and BPD (0.32, \( p = 5.4 \times 10^{-6} \)) and for the SCZ/BPD coheritability (0.37, \( p = 8.5 \times 10^{-8} \), Fig. 2, Supplementary Table 3). For other disorders or pairs of disorders, the estimates explained by CNS+ SNPs do not differ from chance expectation (Supplementary Table 3), although their large standard errors suggest we cannot address this question with precision. For the SCZ/BPD data we also partitioned the heritabilities explained by SNPs by minor allele frequency (MAF) (Supplementary Table 4) and by chromosome (Supplementary Figure 1). The high standard errors on estimates limits interpretation; but the results are consistent with a polygenic architecture of many common variants of small effect dispersed throughout the genome. The MAF partitioning suggests that an important part of the variance explained by SNPs is attributable to common causal variants (this was investigated in detail for SCZ\(^{35}\)), but the low contribution to the total variance explained from SNPs with MAF < 0.1 reflects, at least in part, under-representation of SNPs with low MAF in the analysis (minimum MAF = 0.01) relative to those present in the genome.

**Within disorder heterogeneity**

In order to benchmark the estimates of genetic sharing across disorders, we estimated sharing between data sub-sets of the same disorder. We split the data for each disorder into 2 or 3 independent sets and estimated the SNP-\( h^2 \) from each subset, and the SNP-coheritability between each pair of subsets within a disorder (Fig. 3a, Supplementary Table 5). The estimates of SNP-\( h^2 \) from the data sub-sets are typically higher than the SNP- \( h^2 \) from the combined sample; we note that published estimates from individual cohorts of BPD\(^{36}\), MDD\(^{36}\) and ASD\(^{37}\) were also higher. Since both traits in these data sub-set bivariate analyses are from the same disorder, the SNP-coheritability is also an estimate of the SNP-
$h^2$ for the disorder, but these are generally lower than the estimates of SNP-heritability from individual data sub-sets. These results generate SNP-correlations that are less than one, and sometimes significantly so (Supplementary Table 5). The SCZ/BPD SNP correlation (0.68 s.e. 0.04) is of comparable magnitude as the SNP-correlations between BPD data sets (0.63 s.e. 0.11, 0.88 s.e. 0.09 and 0.55 s.e. 0.10; Fig 3a,b for SNP coheritabilities), adding further weight to the conclusion that SCZ and BPD may be part of the same etiological spectrum.

The estimates of heritability from both univariate (Fig. 3a red/pink bars) and bivariate analyses (Fig. 3a blue bars) are more heterogeneous for BPD, MDD and ADHD than for SCZ and ASD. Several reasons could explain why SNP-heritabilities from univariate analyses of a single data set could generate higher estimates than from bivariate analyses of independent data sets, including loss of real signal or dilution of artefacts. Loss of real signal may occur because individual cohorts are more homogeneous, both phenotypically (e.g., use of the same assessment protocols), and genetically (e.g. because linkage disequilibrium (LD) between causal variants and analyzed SNPs might be higher within than between cohorts).

On the other hand, artefacts could generate consistent differences in case vs control genotypes within case-control data sets. In the derivation of our methodology, we emphasised that any factors making SNP genotypes of cases more similar to other cases, and controls more similar to controls, will produce SNP-heritability. The fitting as covariates of principal components derived from the SNP data corrects both for population stratification and for genotyping artefacts, but residual population stratification could remain, although this bias should be small. Partitioning SNP-heritability by chromosome in analyses where each chromosome is fitted individually compared to analyses where all chromosomes are fitted jointly is an empirical strategy to assess residual stratification and we find no such evidence here (Supplementary Figure 1). Stringent QC helps (as applied here) to remove artefacts, but artefactual differences between cases and controls may remain, particularly
for data sets in which cases and controls have been genotyped independently. As more data sets accumulate, the contributions from artefacts are diluted since the random directional effects of artefacts (including population stratification) are not consistent across data sets. For this reason, significant SNP-coheritabilities are unlikely to reflect artefacts and provide a lower bound on SNP-heritability.

**Pseudo-controls**

One strategy adopted in GWAS to guard against artefacts of population stratification is to genotype trio samples (cases and their parents) and then analyse the data as a case-control sample with controls generated as genomic complements of the cases (i.e. “pseudo-controls”). The ADHD subset 1 and most of the ASD sample are comprised of case-pseudo control samples and, consistent with limiting the impact of artefacts from population stratification or genotyping, it is noted that the lowest SNP-heritability of the 5 psychiatric disorders is for ASD and that the estimate of SNP-heritability is lower for ADHD subset 1 than for ADHD subset 2. However, under a polygenic model, assortative mating or preferential ascertainment of multiplex families could diminish the expected mean difference in liability between pseudo-controls and cases, which would result in an underestimation of SNP-heritability from case/pseudo-control compared to case/control analyses and also non-zero estimates of SNP-heritability from pseudo-control/control analyses as shown in analysis of ASD data.

**Negative control – SNP-coheritabilities with Crohn’s Disease**

As a negative control analysis, we conducted bivariate analyses between each of the PGC data sets with Crohn’s Disease (CD) from the International IBD Genetics Consortium (IIBDGC). While onset of MDD is not uncommon after diagnosis with CD, and while gastrointestinal pathology is commonly comorbid with ASD, there is no strong evidence of
a familial relationship between psychiatric disorders and CD. Despite a substantial SNP-\( h^2 \) for CD (0.19 s.e. 0.01), none of the SNP-coheritabilities with the psychiatric disorders differed significantly from zero (Fig. 3c, Supplementary Table 6, Supplementary Note). Lastly, the genomic partitioning by annotation of variance in CD explained by SNPs showed, as expected, no excess of variance attributable to SNPs in the CNS+ gene set (Fig. 2). Our results provide no evidence for common genetic pleiotropy between CD and ASD consistent with a non-genetic e.g. microbial explanation for the comorbid gastrointestinal symptoms in ASD.

**Potential impact of misclassification of disorders**

Misclassification between disorders could inflate estimates of genetic correlation/coheritability\(^{48}\). Indeed, some level of misclassification between psychiatric disorders is expected. For example, longitudinal studies\(^{49,50}\) of first admissions with psychosis based on research interviews showed that with long term follow-up \(~15\%\) of subjects initially diagnosed with bipolar disorder were re-diagnosed with schizophrenia while \(~4\%\) of schizophrenia diagnoses were re-classified as bipolar disorder. Cases selected for GWAS contributing to PGC to date are more likely to have achieved a stable diagnosis compared to first admission cases. However, assuming these levels of misclassification, the genetic correlation between BPD and SCZ of “true” diagnoses is still high, estimated\(^{48}\) to be 0.55. Likewise, since a modest proportion of cases diagnosed with MDD followed over time ultimately meet criteria for BPD\(^{51}\) our estimated genetic correlation between these two disorders may be modestly inflated by misclassification. On the other hand, if moderate to high genetic correlations between the major adult disorders are true, then overlapping symptoms and misdiagnosis between disorders might be expected. The SNP-\( r_g \) between SCZ and MDD also is unlikely to reflect misdiagnosis since misclassification between these disorders is rare\(^{51}\). Excluding the five of the 18 PGC-SCZ cohorts containing schizoaffective
disorder cases\textsuperscript{21} (Supplementary Table 7) or MDD cohorts ascertained from community rather than clinical settings (Supplementary Table 8) had little impact on the SNP-r

\textbf{DISCUSSION}

Our results show direct, empirical, quantified, molecular evidence for an important genetic contribution to the five major psychiatric disorders. The SNP-$h^2$ estimates for each disorder: SCZ 0.21 (s.e. 0.02), BPD 0.25 (s.e. 0.01), MDD 0.21 (s.e. 0.01), ASD 0.14 (s.e. 0.02), ADHD 0.32 (s.e. 0.02) are considerably less than the heritabilities estimated from family studies (see Table 1). Yet they show that common SNPs make an important contribution to the overall variance, implying that additional individual common SNP associations can be discovered as sample size increases\textsuperscript{52}. SNP- $h^2$ are a lower bound of narrow sense heritability because they exclude contributions from some causal variants (mostly rare variants) not associated with common SNPs. Although the SNP-heritability estimate is similar for MDD as for other disorders, much larger sample sizes will be needed because the high disorder risk implies lower power for the same sample size\textsuperscript{53}. The SNP- $h^2$ are all lower than those reported for height (0.45 s.e. 0.03)\textsuperscript{40} but the estimates are in the same ball-park to those reported for other complex traits and diseases using the same QC pipeline, such as BMI (0.17 s.e. 0.03)\textsuperscript{40}, Alzheimer’s Disease (0.24 s.e.0.03), multiple sclerosis (0.30 s.e.0.03) and endometriosis (0.26 s.e.0.04)\textsuperscript{41}.

Our results show molecular evidence for the sharing of genetic risk factors across key psychiatric disorders. Traditionally, quantification of the genetic relationship between disorders has been thwarted by the need for cohorts of families or twins assessed for multiple disorders. Problems of achieving genetically informative samples of sufficient size and without associated ascertainment biases for the rarer psychiatric disorders have meant that few studies have produced meaningful estimates of genetic correlations. Importantly,
our estimates of heritability and genetic correlation are made using very distant genetic relationships between individuals, both within and between disorders, so that shared environmental factors are unlikely to contaminate our estimates. Likewise, our estimates are unlikely to be confounded by non-additive genetic effects, since the coefficients of non-additive genetic variance between very distant relatives are negligible.

The estimates of SNP-genetic correlation (SNP-r_g) between disorders reflect genome-wide pleiotropy of variants tagged by common SNPs and whether these are the same as correlations across the allelic frequency spectrum may differ between disorder pairs. For example, a high SNP-r_g but a low genetic correlation estimated from family studies (r_g) could reflect that the same common variants contribute to the genetic susceptibility of both disorders, while the diagnostic-specific variants are less common variants. For this reason, the comparison of SNP-r_g with r_g estimated from family studies is not straightforward. Nonetheless we benchmark our estimates in this way, calculating the increased risk of disorder B in first-degree relatives of probands with disorder A (λ_{A,B}) from the SNP-r_g to allow comparison with literature values (Supplementary Table 1). A meta-analysis reported the increased risk of BPD in first-degree relatives of SCZ probands compared to first-degree relatives of control probands (λ_{B} to be 2.1, which implies a maximum genetic correlation between them of 0.3 (assuming that the disorder risks for SCZ and BPD are both 1%, and their heritabilities are 81% and 75%, Table 1). However, a large-scale Swedish family and adoption study estimated the genetic correlation between SCZ and BPD to be +0.60, similar to that found here. Profiling scoring analyses using genome-wide SNPs was the first to demonstrate clearly a genetic relationship based on molecular data, but quantification as a genetic correlation was not reported. The evidence of shared genetic risk factors for SCZ and BPD was strengthened by our analyses of the CNS+ gene set where we saw a clear enrichment in variants shared by these two disorders.
Our finding of a substantial SNP-\( r_g \) of +0.43 between SCZ and MDD is intriguing and contrary to conventional wisdom about the independence of familial risk for these disorders. However, since MDD is common, even a high genetic correlation implies only modest incremental risk. Assuming that the disorder risks and heritabilities for SCZ and MDD in Table 1, then a the genetic correlation between them of 0.43 predicts an increased risk of MDD in first-degree relatives of SCZ probands compared to first-degree relatives of control probands \( (\lambda_{SCZ} \geq 1.6) \). In fact, metaanalysis of five studies interview-based research studies of families are broadly consistent with our results \( (\lambda_{SCZ} \geq 1.5, 95\% \ CI 1.2-1.8) \), suggesting that familial coaggregation of MDD and SCZ reflects genetic effects rather than a consequence of living in a family environment that includes a severely ill family member. If replicated by future work, our empirical molecular genetic evidence of a partly shared genetic etiology for SCZ and MDD has important nosological and research implications, placing MDD as part of a broad psychiatric genetic spectrum. A shared genetic etiology between BPD and MDD has been shown in family studies\(^2,3\) but the SNP-\( r_g \) of 0.47 is lower than the estimate of 0.65 from a twin study\(^57\).

Our results show a small but significant SNP-\( r_g \) between SCZ and ASD. A lower genetic correlation between SCZ and ASD than between SCZ and BPD is consistent with the Swedish national epidemiological studies which reported higher odds ratios in siblings between SCZ and BPD\(^58\) than between SCZ and ASD\(^9\). These results imply a modest overlap of common genetic etiologic processes in these two disorders consistent with emerging evidence from discovery of copy number variants where both shared variants (e.g. 15q13.3, 1q2.1 and 17q12 deletions\(^58,59\)) and same gene but different variants (deletions associated with schizophrenia and duplications associated with autism, and vice versa\(^10\)) have been reported. The small ASD sample size thwarted attempts of further explorative partitioning of the SNP coheritability between SCZ and ASD.
The lack of overlap between ADHD and ASD is surprising and not consistent with family and data linkage studies, which indicate that the two disorders share genetic risk factors\(^5,6,60,61\). Some rare copy number variants are seen in both disorders\(^{16}\). As noted above, the use of pseudo-controls for many of the ASD and ADHD cohorts may impact on all results for these disorders. Ideally we would investigate the impact of pseudo-controls given the hierarchical diagnostic system (autism, but not autism spectrum is an exclusion criterion for most ADHD data sets) on estimates of the SNP-coheritability, but the small ASD sample size prohibits such analyses. We also found no overlap between ADHD and bipolar disorder despite meta-analytic support for an increased risk for ADHD in relatives of BPD I (a subtype of BPD with more extreme manic symptoms than the other major BPD subtype) patients and an increased risk for BPD I in relatives of ADHD patients\(^{12}\). This could mean that the familial link between the two disorders is mediated by environmental risk factors or that the shared genetic factors are not part of the common allelic spectrum. Alternatively, the etiologic link between ADHD and BPD might be limited to BPD I or early onset BPD\(^{12}\) which therefore is difficult for us to detect. Our finding of genetic overlap between ADHD and MDD is consistent with evidence from studies showing increased rates of ADHD in families of depressed probands and increased rates of depression in families of ADHD probands\(^{12,13}\).

Our results should be interpreted in the context of four potentially important methodological limitations. First, any artefacts, that make SNP genotypes more similar between cases than between cases vs. controls could inflate estimates of SNP-heritability\(^{18}\), but to a much lesser extent SNP–coheritability. Second, the sample sizes varied considerably across the five disorders. Although the \(SNP-h^2\) are expected to be unbiased, estimates from smaller samples are accompanied by larger standard errors, blurring their interpretation. Third, while applying similar diagnostic criteria, the clinical methods of ascertainment and the specific study protocols, including which specific interview instruments were employed, varied across sites. We cannot now determine the degree to which our results might have
been influenced by the between-site differences in the kinds of patients seen or in their assessments. Fourth, by combining samples from geographical regions, contributions from less common associated variants specific to populations are diluted compared to what could be achieved if the same sample size had been ascertained from a single homogeneous population.

In summary, we report SNP-heritabilities that are significantly greater than zero for all five disorders studied. We have used the largest psychiatric GWAS data sets currently available and our results provide important pointers for future studies. Our results demonstrate that the dearth of significant associations from psychiatric GWAS to date, particularly for MDD, ASD and ADHD, reflects lack of power to detect common associated variants of small effect rather than absence of such variants. Hence as sample sizes increase the success afforded to other complex genetic diseases in progressing understanding of their etiology is achievable for psychiatric disorders, as already being shown for SCZ. We also provide evidence for a substantial sharing of the genetic risk variants “tagged” by these SNPs for SCZ/BPD, BPD/MDD, SCZ/MDD, ADHD/MDD and, to a lesser extent, SCZ/ASD. Our results will likely contribute to efforts now underway to base psychiatric nosology on a firmer empirical footing. Furthermore, they will encourage investigations into shared pathophysiologies across disorders including potential clarification of common therapeutic mechanisms.
Note: Supplementary information is available on the Nature Genetics website.

Acknowledgements

This research was directly supported by the Australian Research Council (FT0991360, DE130100614) and the Australian National Health and Medical Research Council (613608, 1011506, 1047956). The PGC-CDG is supported by NIMH grant U01 MH085520. Statistical analyses were carried out on the Genetic Cluster Computer (http://www.geneticcluster.org) which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003 PI Posthuma) along with a supplement from the Dutch Brain Foundation and the VU University Amsterdam. Numerous (>100) grants from government agencies along with substantial private and foundation support world-wide enabled the phenotype and genotype data collection without which this research would be not be possible; the grants are listed in the primary PGC publications or in the Supplementary Note.
Author Contributions


COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.
Figure 1. Evidence for genome-wide pleiotropy between psychiatric disorders. a. Proportion of variance in liability (SNP-heritability), and proportion of covariance in liability between disorder (SNP-coheritability) for 5 major psychiatric disorders. 95% error bars are estimate $\pm$ 1.96 standard error.

Figure 2: Genomic partitioning of SNP-heritability/SNP-coheritability by annotation. Proportion of SNPs attributable to genes in CNS+ set (red bar), proportion of SNP-heritability explained by SNPs attributed to SNPs in CNS+ set (dark green bar), proportion of SNP-coheritability attributed to SNPs in CNS+ set (light green bar), proportion of SNP-heritability for Crohn’s Disease attributed to SNPs in CNS+ set (orange bar). 95% error bars are estimate $\pm$ 1.96 standard error. *** p< $10^{-5}$ from test that proportion of heritability explained by SNPs = proportion of SNPs.

Figure 3: SNP-heritabilities and coheritabilities. a) For each disorder the SNP-heritabilities are estimated from univariate analyses of the full data set (dark green bars) or from subsets (red/pink bars). They are also estimated from bivariate analyses in which different subsets of the same disorder comprise the two traits (blue bars). Test of heterogeneity of estimates, p-value for Cochrane’s Q, SCZ: 0.3, BPD: $1x10^{-6}$, MDD: 4 x10^{-3}, ADHD: 9x10^{-6}, ASD: 0.99 Higgins’ I2, SCZ: 21%, BPD: 86%, MDD: 71% ADHD: 91% ASD:0 b) For comparison the coheritabilities using the full data sets from Figure 1. c) As a negative control, estimates of coheritabilities with Crohn’s Disease (CD), a disease not expected to be genetically related to psychiatric disorders. 95% error bars are estimate $\pm$ 1.96 standard error.
Table 1. Univariate analyses: sample description, SNP-heritabilities and recurrence risk to first-degree relatives

<table>
<thead>
<tr>
<th></th>
<th>SCZ</th>
<th>BPD</th>
<th>MDD</th>
<th>ASD</th>
<th>ADHD</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNPs(Imputed)</td>
<td>915354</td>
<td>995971</td>
<td>962093</td>
<td>982100</td>
<td>917066</td>
</tr>
<tr>
<td>Cases</td>
<td>9087</td>
<td>6704</td>
<td>9041</td>
<td>3303</td>
<td>4163</td>
</tr>
<tr>
<td>Controls</td>
<td>12171</td>
<td>9031</td>
<td>9381</td>
<td>3428</td>
<td>12040</td>
</tr>
<tr>
<td>N cohorts</td>
<td>17</td>
<td>11</td>
<td>9</td>
<td>8</td>
<td>8</td>
</tr>
</tbody>
</table>

Primary Reference

<table>
<thead>
<tr>
<th></th>
<th>21</th>
<th>22</th>
<th>23</th>
<th>24,25</th>
<th>26-30</th>
</tr>
</thead>
</table>

Disorder risk for the study-base population (disorder risk, \( K \)) used in Figures and Supplementary Tables

<table>
<thead>
<tr>
<th></th>
<th>0.01</th>
<th>0.01</th>
<th>0.15</th>
<th>0.01</th>
<th>0.05</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNP-( h^2 ) (s.e.)</td>
<td>0.23 (0.008)</td>
<td>0.25 (0.012)</td>
<td>0.21 (0.021)</td>
<td>0.17 (0.023)</td>
<td>0.28 (0.023)</td>
</tr>
<tr>
<td>( \lambda_{\text{1st-SNP}} ) (s.e)</td>
<td>2.10 (0.05)</td>
<td>2.23 (0.08)</td>
<td>1.27 (0.03)</td>
<td>1.75 (0.14)</td>
<td>1.71 (0.07)</td>
</tr>
<tr>
<td>( \lambda_{\text{1st}} )</td>
<td>8.8</td>
<td>9.6</td>
<td>1.5</td>
<td>8.7</td>
<td>3.5</td>
</tr>
</tbody>
</table>

Lower bound for disorder risk (\( K \))

<table>
<thead>
<tr>
<th></th>
<th>0.004</th>
<th>0.007</th>
<th>0.1</th>
<th>0.001</th>
<th>0.03</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNP-( h^2 ) (s.e.)</td>
<td>0.19 (0.007)</td>
<td>0.23 (0.010)</td>
<td>0.19 (0.020)</td>
<td>0.11 (0.017)</td>
<td>0.24 (0.020)</td>
</tr>
<tr>
<td>( \lambda_{\text{1st-SNP}} ) (s.e)</td>
<td>2.14 (0.06)</td>
<td>2.25 (0.08)</td>
<td>1.31 (0.03)</td>
<td>1.79 (0.15)</td>
<td>1.77 (0.07)</td>
</tr>
<tr>
<td>( \lambda_{\text{1st}} )</td>
<td>14.4</td>
<td>11.7</td>
<td>1.7</td>
<td>29.4</td>
<td>4.5</td>
</tr>
</tbody>
</table>

Upper bound for disorder risk (\( K \))

<table>
<thead>
<tr>
<th></th>
<th>0.012</th>
<th>0.015</th>
<th>0.2</th>
<th>0.015</th>
<th>0.08</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNP-( h^2 ) (s.e.)</td>
<td>0.24 (0.009)</td>
<td>0.27 (0.013)</td>
<td>0.23 (0.023)</td>
<td>0.19 (0.028)</td>
<td>0.32 (0.026)</td>
</tr>
<tr>
<td>( \lambda_{\text{1st-SNP}} ) (s.e)</td>
<td>2.10 (0.05)</td>
<td>2.20 (0.07)</td>
<td>1.24 (0.02)</td>
<td>1.74 (0.13)</td>
<td>1.65 (0.06)</td>
</tr>
<tr>
<td>( \lambda_{\text{1st}} )</td>
<td>8.0</td>
<td>7.7</td>
<td>1.4</td>
<td>7.0</td>
<td>2.8</td>
</tr>
</tbody>
</table>

Heritability estimated from twin/family studies\(^{63}\)

\( h^2 \)

|               | 0.81    | 0.75    | 0.37    | 0.80    | 0.75    |

SCZ: schizophrenia, BPD: bipolar disorder, MDD: major depressive disorder, ASD: autism spectrum disorders, ADHD: attention deficit hyperactivity disorder. CC=SNP-heritability estimated on case-control scale. SNP-\( h^2 \) SNP-heritability on liability scale given assumed \( K \).

All estimates of SNP-\( h^2 \) are highly significantly different from zero. \( \lambda_{\text{1st-SNP}} \) recurrence risk to first degree relatives calculated from SNP-\( h^2 \) liability and \( K \). \( \lambda_{\text{1st}} \) recurrence risk to first degree relatives calculated from \( h^2 \) from twin/family studies and \( K \). a) some cohorts include cases and pseudo-controls where pseudo-controls are the genomic complements of the cases derived from genotyping of proband-parent trios.
Methods

Data & quality control (QC)

A summary of the data available for analysis is listed in Table 1 and comprise data used in the PGC-Cross Disorder Group analysis together with newly available ADHD samples. Data upload to the PGC central server follows strict guidelines to ensure local ethics committee approval for all contributed data. Data from all study cohorts were processed through the stringent PGC pipeline. Imputation of autosomal SNPs used the CEU+TSI Hapmap Phase 3 data as the reference panel. For each analysis (univariate or bivariate), we retained only SNPs that had minor allele frequency > 0.01 and imputation R² > 0.6 in all contributing cohort sub-samples (imputation cohorts). Different QC strategies were investigated in detail for the raw and PGC imputed genotyped data of the International Schizophrenia Consortium, a subset of the PGC SCZ sample. The CD samples from the International IBD Genetics Consortium (IIBDGC) were processed through the same QC and imputation pipeline as the PGC data, generating a data set of 5054 cases and 11496 controls from 6 imputation cohorts.

In each analysis, individuals were excluded to ensure that all cases and controls were completely unrelated in the classical sense, so that no pairs of individuals had a genome-wide similarity relationship greater than 0.05 (equivalent to about second-cousins). This procedure removed ancestry outliers (over and above those already removed in the PGC QC pipeline, Supplementary Figures 2-5) and ensured that overlapping control sets were allocated randomly between disorders in the bivariate analyses. Exact numbers of cases and controls used in each analysis are listed in Supplementary Tables 1-8.

Linear mixed model for estimation of SNP-heritability and SNP-coheritability
We use the methods presented in Lee et al. Briefly, we estimate the variance in case-control status explained by all SNPs using a linear mixed model,

\[ y = X\beta + g + e \]  

(1)

where \( y \) is a vector of case (=1) or control (=0) status (the “observed scale”), \( \beta \) is a vector for fixed effects of the overall mean (intercept), sex, sample cohort and 20 ancestry principal components, \( g \) is the vector of random additive genetic effects based on aggregate SNP information, and \( e \) is a vector of random error effects. \( X \) is an incidence matrix for the fixed effects relating these effects to individuals. The variance structure of phenotypic observations is \( V(y) = \sigma_g^2 A + \sigma_e^2 I \), where \( \sigma_g^2 \) is additive genetic variance tagged by the SNPs, \( \sigma_e^2 \) is error variance, \( A \) is the realized similarity relationship matrix estimated from SNP data and \( I \) is an identity matrix. All variances are estimated on the observed case-control scale and are transformed to the liability scale, which requires specification of the disorder risk, \( K \), to estimate SNP-\( h^2 \). Risk to first-degree relatives is calculated from \( K \) and SNP-\( h^2 \) based on the liability threshold model.

The bivariate analyses use a bivariate extension of equation (1). The two traits are measured on different individuals, but the equations are related through the genome-wide similarities estimated from SNPs. Genetic and residual variances for the traits are estimated as well as the genetic covariance \( g_{12} \). The genetic correlation coefficient (\( r_g \)) is

\[ r_g = \frac{g_{12}}{\sqrt{\sigma_g^2 \sigma_g^2}} \]

and is approximately the same on the observed case-control scale as on the liability scale so does not depend on specifications of \( K \). The covariance, \( g_{12} \), can be transformed to the liability scale accounting for assumed disorder risks and proportions of cases and controls in the samples of each disorder and it equals the coheritability \( r_g h_1 h_2 \).

We used the approximated chi-square test statistic (estimate/s.e.)\(^2\) to test if estimates were significantly different from zero. We checked that this simple approximation agreed well with the more formal and computer-intensive likelihood ratio test for several examples.
Heterogeneity of SNP-heritabilities was tested using Cochran’s $Q$ and Higgins’ $I^2$, acknowledging potential non-independence of the 6 estimates (3 subsets plus 3 subset pairs).

**Disorder risk for the study-base population (disorder risk, $K$)**

The estimates of SNP-$h^2$ and SNP-coheritability from the linear model are on the case-control scale and so depend partly on the proportion of cases and controls in the sample.

The transformation to the liability scale allows benchmarking of SNP-$h^2$ to estimates of heritability from family studies, and the transformation accounts for the proportion of cases in the sample and depends on the assumed disorder risk ($K$). The appropriate choice of $K$ depends on the definitions of both the phenotype (including ascertainment strategy) and the population, which may differ between cohorts. We consider lower and upper bounds for $K$ in Table 1 to cover the range of possible values. SNP-$r_g$ estimates are independent of scale and hence are not dependent on the choice of $K$.

**Genome partitioning linear mixed model**

We partitioned the variance explained by the SNPs in several ways. For example, for the univariate linear model $\mathbf{y} = \mathbf{X} \beta + \sum_{t=1}^{n} \mathbf{g}_t + \mathbf{e}$ with $V(\mathbf{y}) = A_t \sum_{t=1}^{n} g_{te}^2 + I \sigma_e^2$, where $n$ is the number of subsets from any non-overlapping partitioning of SNPs; $n = 22$ for the joint analysis by chromosome, $n = 5$ for the analysis by MAF bin and $n = 3$ for the analysis of SNP by gene annotation in which SNPs were classed as “CNS+ genes” (2,725 genes representing 547 Mb), SNPs in “other genes” (14,804 genes representing 1,069 Mb) and the remaining SNPs “not in genes”. Gene boundaries as ± 50kb from 3’ and 5’ UTRs of each gene and the CNS+ genes were the four sets identified by Raychaudhuri et al. (one set comprised genes expressed preferentially in the brain compared to other tissues and the other three sets comprised genes annotated to be involved in neuronal activity, learning and synapses). The CNS+ set was found to explain more of the SNP-heritability than expected by
chance for schizophrenia\textsuperscript{35}. All methods have been implemented into the freely available GCTA software\textsuperscript{67}. 
References


Italy. 34Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Dresden, Germany. 35Centro Nacional de Análisis Genómico (CNAG), Parc Científic de Barcelona (PCB), Catalonia, Spain. 36INSERM, U955, Psychiatrie Génétique, Créteil, France. 37Université Denis Diderot, Paris, France. 38Assistance Publique–Hôpitaux de Paris (AP-HP), GH Saint-Louis, Lariboisière, F Widal, Département de Psychiatrie, Paris, France. 39ENBREC group, Fondation FondaMental, Créteil, France. 40Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 41Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA. 42INSERM U952, Paris, France. 43CNRS UMR 7224, Paris, France. 44UPMC University of Paris, Paris, France. 45Max Planck Institute of Psychiatry, Munich, Germany. 46Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 47Department of Psychiatry, University of Iowa, Iowa City, IA, USA. 48Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK. 49The Scripps Translational Science Institute and Scripps Health, La Jolla, CA, USA. 50School of Public Health, University of Michigan, Ann Arbor, MI, USA. 51Department of Biological Psychology, VU University, Amsterdam, The Netherlands. 52EMGO Institute for Health and Care Research, Amsterdam, The Netherlands. 53Neuroscience Campus Amsterdam, The Netherlands. 54National Institute of Health Research Biomedical Research Centre for Mental Health, South London, London, UK. 55Maudsley NHS Trust & Institute of Psychiatry, London, UK. 56Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 57Department of Psychiatry, University of Groningen, Groningen, The Netherlands. 58School of Nursing, Louisiana State University Health Sciences Center, New Orleans, LA, USA. 59Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Centre, Nijmegen, The Netherlands. 60Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA. 61Department of Psychiatry, University of California, San Francisco, CA, USA. 62NCIRE (Northern California Institute of Research And Education), San Francisco, CA, USA. 63Department of Psychiatry, Birmingham University, Birmingham, UK. 64Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands. 65Netherlands. 66David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 67Department of Psychiatry, Hospital Universitari Vall d’Hebron, CIBERSAM, Catalonia, Spain. 68Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain. 69Department of Mental Health Sciences, University College London, London, UK. 70Department of Genomics, University of Bonn, Bonn, Germany. 71Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, Jülich, Germany. 72Institute of Human Genetics, University of Bonn, Bonn, Germany. 73Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA. 74Institute for Juvenile Research, Department of Psychiatry, University of Illinois, Chicago, IL, USA. 75Department of Psychiatry, University of Utah, Salt Lake City, UT. 76Departament de Genètica, Facultat de Biologia, Universitat de Barcelona, Catalonia, Spain. 77Biomedical Network Research Centre on Rare Diseases (CIBERER), Catalonia, Spain. 78Institut de Biomedicina de la Universitat de Barcelona (IBUB), Catalonia, Spain. 79The Translational Genomics Research Institute, Phoenix, AZ, USA. 80The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. 81John P Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA. 82East London NHS Foundation Trust, Queen Mary, University of London, London, UK. 83Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. 84Genetics Institute, University College London, London, UK. 85Autism Speaks, New York, NY, USA. 86Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 87Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 88Division of Neuroscience, Medical Research Institute, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK. 89Department of Medical Genetics, Oslo University Hospital, Oslo, Norway. 90Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 91Department of Psychiatry and Behavioral Sciences, NorthShore University Health System and University of Chicago, Evanston, IL, USA. 92Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. 93Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, J W Goethe University Frankfurt, Frankfurt, Germany. 94Psychology Department, National University of Singapore, Singapore. 95Department of Biochemistry and Molecular Biology, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA. 96Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA. 97Al Dupont Hospital for Children, University of Pennsylvania, Philadelphia, PA, USA. 98School of Medicine,
Medical Science University College, Dublin, Ireland. 99 Université Paris Est, Faculté de Médecine, Créteil, France. 108 Assistance Publique–Hôpitaux de Paris (AP–HP), Hôpital H Mondor–A Chenevier, Département de Psychiatrie, Créteil, France. 101 Department of Psychiatry, Georgetown University School of Medicine, Washington DC, USA. 109 Virginia Institute of Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA. 103 Institutes of Neuroscience, Newcastle University, Newcastle upon Tyne, UK. 104 Department of Psychiatry, Oregon Health & Science University, Portland, OR USA. 105 Institute for Development & Disability, Oregon Health & Science University, Portland, OR USA. 106 MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK. 107 Department of Psychological Medicine and Neurology, Cardiff University, Cardiff, UK. 108 Department of Psychiatry, University of Colorado Denver, Aurora, CO, USA. 109 UCLA Center for Neurobehavioral Genetics, University of California, Los Angeles, CA, USA. 110 Department of Psychiatry, University of Halle, Halle, Germany. 111 Department of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. 112 Department of Psychiatry, Trinity College, Dublin, Ireland. 113 Institute of Medical Biometry, University of Bonn, Bonn, Germany. 114 Department of Psychiatry, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 115 Center for Autism Research and Treatment, Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 116 Queensland Institute of Medical Research, Brisbane, QLD, Australia. 117 Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK. 118 Department of Biomedical and Biological Sciences, Plymouth University, Plymouth, UK. 119 Department of Psychiatry, University of California San Diego, La Jolla, CA, USA. 120 Department of Psychiatry, University of Bonn, Bonn, Germany. 121 Department of Psychiatry, AMC, University of Amsterdam The Netherlands. 122 Center for Human Genetics Research, Vanderbilt University Medical Centre, Nashville, TN, USA. 123 The Center for Applied Genomics, Division of Human Genetics, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA. 124 Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. 125 Department of Psychiatry, School of Medicine, Stanford University, Stanford, CA 94305, USA. 126 Biostatistics and Bioinformatics Unit, Cardiff University, Cardiff, UK. 127 Institute of Biological Psychiatry, Copenhagen University Hospital, Roskilde, Denmark. 128 Department of Clinical and Developmental Psychology, Institute of Psychology, University of Tübingen, Tübingen, Germany. 129 Brain and Mind Research Institute, University of Sydney, Sydney, NSW, Australia. 130 Department of Psychiatry and Behavioral Sciences, Howard University College of Medicine, Washington, DC, USA. 131 Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands. 132 Department of Psychology, University of Michigan, Ann Arbor, MI, USA. 133 Center for Neuroscience, University of California, Davis, CA, USA. 134 Bioinformatics Research Center, North Carolina State University, Raleigh, NC, USA. 135 Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, Utrecht, The Netherlands. 136 Department of Psychology, University of Colorado, Boulder, CO, USA. 137 Psychiatric Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. 138 School of Medicine, University of St Andrews, St Andrews, UK. 139 Department of Genetics, University of North Carolina, Chapel Hill, NC, USA. 140 Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany. 141 Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 142 University of Southern California, Los Angeles, CA, USA. 143 Queen Mary University of London, London, UK. 144 Maastricht University Medical Centre, South Limburg Mental Health Research and Teaching Network, Maastricht, The Netherlands. 145 University College London, London, UK. 146 Department of Biostatistics and Center for Statistical Genetics, School of Public Health, University of Michigan, Ann Arbor, MI, USA. 147 Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden. 148 Centre National de Genotypage, Evry, France. 149 Molecular Psychiatry Laboratory, Research Department of Mental Health Sciences, University College London Medical School, London, UK. 150 Geisinger Health System, Autism and Developmental Medicine Institute, Danville, PA, USA. 151 Department of Psychiatry, Division of Research, The Zucker Hillside Hospital Division of the North Shore, Long Island Jewish Health System, Glen Oaks, NY, USA. 152 Center for Psychiatric Neuroscience, The Feinstein Institute of Medical Research, Manhasset, NY, USA. 153 Department of Psychiatry and Behavioral Science, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA. 154 Division of Molecular Psychiatry, ADHD Clinical Research Unit, Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany. 155 Department of Neuroscience, School for Mental Health and Neuroscience (MHENS), Maastricht University, The Netherlands. 156 Department of Psychology and Behavioral Sciences, Stanford University, Stanford, CA, USA. 157 Department of Human Genetics,
School, Boston, MA, USA. 224Clinical Neuropsychology, VU University, Amsterdam, The Netherlands. 225Psychiatry and Behavioral Science, Stanford University School of Medicine, Palo Alto, CA, USA. 226Rush University Medical Center, Chicago, IL, USA. 227Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA. 228The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON, Canada. 229The Scripps Translational Science Institute, La Jolla, CA, USA. 230The Scripps Research Institute, La Jolla, CA, USA. 231Department of Psychiatry & Psychotherapy, University of Göttingen, Göttingen, Germany. 232Psychiatric Center Nordbaden, Wiesloch, Germany. 233Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. 234Department of Psychiatry and Behavioural Science, University of Washington, Seattle, WA, USA. 235Mayo Clinic, Rochester, MN, USA. 236Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA. 237Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands. 238Developmental Brain & Behaviour Laboratory, University of Southampton, Southampton, UK. 239Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK. 240Research Department, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany. 241Research Unit of Child and Adolescent Psychiatry, Aalborg University Hospital, Aalborg, Denmark. 242Clinical Psychology and Epidemiology, University of Basel, Switzerland. 243Department of Child and Adolescent Psychiatry, University of Zurich, Switzerland. 244Social, Genetic and Developmental Psychiatry (SGDP) Centre, The Institute of Psychiatry, King’s College London, London, UK. 245Vanderbilt University, Nashville, TN, USA. 246Department of Psychiatry University of Toronto, Toronto, Ontario Canada. 247Hospital for Sick Children, Toronto, Ontario Canada. 248Centre for Addiction and Mental Health, Toronto, Ontario Canada. 249West Berkshire NHS Trust, University College London, London, UK. 250Center for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, Richmond, VA, USA. 251Instituto Nacional de Saude Dr Ricardo Jorge, Lisbon, Portugal. 252BioFIG—Center for Biodiversity, Functional and Integrative Genomics, Campus da FUCUL, Campo Grande, Lisbon, Portugal. 253Instituto Gulbenkian de Ciencia, Lisbon, Portugal. 254Nationwide Children’s Hospital, Columbus, OH, USA. 255Molecular Neuropsychiatry and Development Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada. 256The University of Queensland, Diamantina Institute, Brisbane, QLD, Australia. 257Howard Hughes Medical Institute, Children’s Hospital Boston, Boston, MA, USA. 258Division of Genetics, Children’s Hospital Boston, Boston, MA, USA. 259Neurology and Pediatrics, Harvard Medical School Center for Life Sciences, Boston, MA, USA. 260Columbia University College of Physicians and Surgeons, New York, NY, USA. 261Department of Biostatistics, University of Washington, Seattle, WA, USA. 262Department of Medicine, University of Washington, Washington, Seattle, WA, USA. 263Centre for Affective Disorders, Institute of Psychiatry, King’s College London, UK. 264Division of Genetics, Children’s Hospital Boston, Harvard Medical School, Boston, MA, USA. 265Department of Mental Health, Johns Hopkins University, Baltimore, MD, USA. 266Leiden University Medical Center, Leiden, The Netherlands. 267Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA. 268A list of members is provided in the Supplementary Note. 269Department of Psychiatry, Special Treatment and Evaluation Program (STEP), Veterans Affairs San Diego Healthcare System, San Diego, CA, USA. 270Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA. 271Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA. * These authors contributed equally. ¶Correspondence should be addressed to N.R.W (naomi.wray@uq.edu.au).